New financing
New financingFINANCING ISSUE
Crossject has announced the issuance of convertible bonds.
It also grants free subscription rights to existing shareholders.
The financing of FY22 is thus secured and gives the group time to reach the market.
We will fine-tune our model and integrate this issuance.
FACT
Crossject has just announced the issuance of convertible bonds and the free granting of subscription rights to its shareholders.
ANALYSIS
In an unsurprising move, the group announced it has issued €7.5m in convertible bonds (no coupon, issued at 92% of its nominal value and maturing on 31 December 2024), including €1.5m by Gemmes Venture, its main shareholder, and other qualified investors. The conversion price will be the minimum between €3.30 and 92% of a weighted average share price during a period before the conversion. The group also announced that existing shareholders (as at 31 December 2021) will be granted free subscription rights, every 20 rights enabling them to buy a share at a price of €3 between 12 January and 30 June 2022. This could lead to the issuance of 1.3m shares and a strengthening of shareholders’ funds by €3.9m.
Altogether (i.e. including convertible bonds) the group could raise as much as €11.5m during FY22 (without taking into account potential licensing revenues or subsidies) which should rather easily fill its needs for the coming year.
Looking beyond FY22, the visibility is less clear since it is still too early to assess the potential cash inflows that could benefit the company during the coming year. However, we take the news as rather good since it secures FY22 and shows once again the confidence of its main shareholders.
IMPACT
We will adjust our numbers to take into account the convertible issuance.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.